Sanofi shares break through €87.98 and reach a 250-session high
The pharmaceutical company extends its strong rebound in a virtually stable CAC 40. The stock passes a level monitored for several weeks and climbs to the top of the index ranking.
A breakout that lifts the stock beyond its levels of the year
Sanofi gains 0.95% to €88.43, ranking among the top of the CAC 40, while the index rises only 0.04%.
During the session, the stock broke upward through €87.98, which corresponds to its highest level of the past 30, 150 and 250 sessions. This former resistance now becomes support, and the next round level is at €90.
The move extends a marked rebound: +22.55% over one month and +5.6% over one week. The RSI at 82 signals an overbought configuration, while the price remains 9.6% above the MM20 moving average, at €80.68. The 250-session high had already been mentioned on Thursday, before the stock surpassed it today.
A valuation of 9.9 times expected earnings, following raised targets
This rebound follows a third quarter with a 14.3% increase, published on October 30, during which the group raised its 2026 targets. Following this sequence, the stock trades at approximately 9.9 times current-year earnings and 9.4 times next-year earnings, according to the consensus of the analysts surveyed.
Expected earnings per share growth stands at +6.4%. Over twelve months, performance remains slightly negative at -1.3%, which places the recent rebound in a catch-up context. The next technical level identified is the €90 mark, while the €87.98 level broken today now constitutes the reference point below the price.